Eli Lilly (LLY 2.01%) just delivered 45% revenue growth and guided toward $83 billion in 2026 sales. With blockbuster obesity drugs, multiple growth catalysts, and analysts targeting $1,500, this healthcare powerhouse may still have substantial upside ahead for long-term investors.
Stock prices used were the market prices of Feb. 13, 2026. The video was published on Feb. 17, 2026.





